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cancer cells to TNF-a therapy
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Geoffrey W Krissansen1*
Abstract
Background: Survivin is a member of the inhibitor-of-apoptosis (IAP) family which is widely expressed by many
different cancers. Overexpression of survivin is associated with drug resistance in cancer cells, and reduced patient
survival after chemotherapy and radiotherapy. Agents that antagonize the function of survivin hold promise for
treating many forms of cancer. The purpose of this study was to investigate whether a cell-permeable dominant-
negative survivin protein would demonstrate bioactivity against prostate and cervical cancer cells grown in three
dimensional culture.
Results: A dominant-negative survivin (C84A) protein fused to the cell penetrating peptide poly-arginine (R9) was
expressed in E. coli and purified by affinity chromatography. Western blot analysis revealed that dNSurR9-C84A
penetrated into 3D-cultured HeLa and DU145 cancer cells, and a cell viability assay revealed it induced cancer cell
death. It increased the activities of caspase-9 and caspase-3, and rendered DU145 cells sensitive to TNF-a via by a
mechanism involving activation of caspase-8.
Conclusions: The results demonstrate that antagonism of survivin function triggers the apoptosis of prostate and
cervical cancer cells grown in 3D culture. It renders cancer cells sensitive to the proapoptotic affects of TNF-a,
suggesting that survivin blocks the extrinsic pathway of apoptosis. Combination of the biologically active dNSurR9-
C84A protein or other survivin antagonists with TNF-a therapy warrants consideration as an approach to cancer
therapy.
Background
Survivin is a member of the inhibitors of apoptosis
(IAP) family. Overexpression of survivin renders cancer
cells resistant to anti-cancer therapy including che-
motherapy and radiation therapy [1-5]. It causes oral
cancer cells to be resistant to the anti-mitotic com-
pounds vincristine and colchicine, such that down-regu-
lation of survivin restores their drug sensitivity [2].
Overexpression of survivin inhibited the tamoxifen and
cisplatin-induced apoptosis of human breast and gastric
cancer cells [3,5]. It enhanced the repair of DNA dou-
ble-strand breaks in radiation-treated oral cancer cells
by upregulating the molecular sensor of DNA damage,
Ku70 [4]. The level of survivin expression was inversely
related to the degree of apoptosis, and positively related
to the risk of local tumor recurrence in rectal cancer
patients treated with radiotherapy [6]. Patients with gas-
tric tumors that express low levels of survivin appear to
have a longer mean survival time after cisplatin treat-
ment than patients with high levels of expression [5].
Survivin expression is associated with the metastasis of
human prostate cancer to bone [7]. Thus, survivin plays
an important role in tumorigenesis and tumor metasta-
sis, and where levels of survivin expression serve as an
indicator of therapeutic effectiveness.
At the molecular level, survivin is bifunctional in that
it is a suppressor of apoptosis and plays a central role in
cell division. A study using surface plasmon resonance
spectroscopy and immunoprecipitation analysis showed
that a recombinant survivin protein was able to bind
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directly to both caspase-3 and caspase-7 with nanomolar
affinity [8]. Targeting of survivin by siRNA induces the
activation of caspase-9 and caspase-3 in various cancer
cells [8,9]. It appears to be mitochondrial survivin rather
than cytosolic survivin that inhibits apoptosis through
interference with caspases [8,10,11]. Survivin also plays
a role in inhibiting the caspase-independent apoptosis of
cancer cells [12]. Translocation of the apoptosis-indu-
cing factor (AIF) from the cytoplasm to the nucleus is a
molecular indicator of the caspase-independent apopto-
sis of cells. Down-regulation of survivin by siRNA
induces the translocation of AIF from the cytoplasm to
the nucleus in various cancer cells [12].
Progress in the development of survivin inhibitors has
been slow despite the fact that survivin plays multiple
roles in cancer cell survival, and renders cancers insensi-
tive to chemotherapy. In the past ten years only a few
small molecule inhibitors of survivin have been devel-
oped and only one survivin inhibitor, YM155, has
reached clinical trials [13-17]. Therefore, it is of interest
to identify novel macromolecular inhibitors of survivin,
and to explore their clinical utility. The 3D-structure of
survivin has been determined by x-ray crystallography,
which together with the gene sequence reveals that the
16.5 kDa survivin protein monomer comprises an N-
terminal Zn2+-binding baculovirus IAP repeat (BIR)
domain consisting of a three-stranded anti-parallel b-
sheet surrounded by four small a helices that is linked
to a 65 A° amphipathic C-terminal a-helix [18-20]. Sur-
vivin exists as a dimer and has an extensive dimerization
interface along a hydrophobic surface on the BIR
domain of each survivin monomer. Mutagenesis studies
have shown that the BIR domain plays a key role in the
anti-apoptotic function of survivin. Thus, point muta-
tions such as C84A in the BIR domain prevent requisite
dimerization of survivin, producing a dominant-negative
mutant that interferes with the anti-apoptotic function
of native survivin [21-23]. A Thr34 residue is located at
the amino-terminal end of helix II of the BIR, sur-
rounded by a sequence that matches the consensus
phosphorylation site S/T-P-X-R for the mitotic kinase
complex, p34cdc2-cyclin B1. Mutation of Thr34 to Ala
(T34A) removes the phosphorylation site and prevents
survivin from binding to activated caspase-9, creating a
dominant-negative survivin molecule that disrupts cell
division and induces apoptosis [24-26]. These and other
dominant-negative forms of survivin are macromolecu-
lar inhibitors that have potential utility in the treatment
of cancer.
Here we created a cell-permeable dominant-negative
C84A survivin protein and investigated its biological
activity against cancer cells grown in 3D culture.
Results
Production of a cell-permeable dominant-negative C84A
survivin protein
A GST-tagged dominant-negative survivin protein
(dNSurR9-C84A) was constructed based on the finding
that mutation of Cys84 to Ala in the extreme C-term-
inal region of the BIR domain of survivin completely
abrogates survivin’s ability to inhibit apoptosis, trans-
forming it into a dominant-negative inhibitor of survivin
function [21]. The 5’-end of the cDNA sequence encod-
ing dNSurR9-C84A was fused to a sequence encoding
nine arginine residues (poly-arginine or R9 sequence)
based on the finding that proteins fused with a poly-
arginine carrier peptide are efficiently taken up by cells
[27]. The pGEX-2T/dNSurR9-C84A construct encoding
cell-permeable dNSurR9-C84A was transformed into
BL21 E.coli cells and its expression induced with IPTG.
SDS-PAGE analysis revealed an expressed protein of
~42 kDa in size that matched the expected molecular
weight of recombinant dominant-negative survivin of 17
kDa fused to GST of 25 kDa (Figure 1A). Western blot
analysis with an anti-survivin antibody confirmed that
the ~42 kDa protein was GST-tagged dNSurR9-C84A,
and that it was mostly expressed in the soluble fraction
(Figure 1B). The dNSurR9-C84A protein was purified by
glutathione affinity chromatography, giving a single pro-
duct of 42 kDa (Figure 1C).
A preliminary study revealed that dNSurR9-C84A was
able to penetrate into human DU145 prostate cancer
cells in two dimensional (2D) cultures within 30 min of
addition of the protein (Additional file 1) [28]. Here, the
ability of dNSurR9-C84A to penetrate into 3D cultured
cancer cells grown in semi-solid media containing
Matrigel™was examined. DU145 prostate cancer and
HeLa epithelial cervical cancer cells grown as 3D cul-
tures (Figure 1D) were incubated with either PBS con-
trol or dNSurR9-C84A (20 μg/mL) for 1 to 5 h, and the
cytosolic fraction of the cells was subjected to Western
blotting. Cytosolic appearance of dNSurR9-C84A in
DU145 and HeLa cells was observed as early as 1 to 2 h
after addition of dNSurR9-C84A (Figure 1E).
dNSurR9-C84A reduces the viability of DU145 and HeLa
cancer cells
The effect of dNSurR9-C84A on the viability of 3D cul-
tures of DU145 and HeLa cells, which endogenously
express survivin as assessed by Western blot analysis
(Figure 2A), was examined. A preliminary study revealed
that treatment of 2D-cultured DU145 and HeLa cancer
cells with dNSurR9-C84A for 24 h induced caspase-3-
associated apoptosis, whereas similar treatment did not
effect survivin-independent human umbilical vein
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Figure 1 Production of dNSurR9-C84A. (A) SDS-PAGE analysis of proteins in bacteria transformed with pGEX-2T/dNSurR9-C84A. Bacteria were
lysed before IPTG induction and 3 h after IPTG induction of protein expression. Analysis of the total lysate and insoluble and soluble fractions
revealed a major ~42 kDa protein (position is indicated in the right-hand margin) induced by IPTG. Lane MW, molecular weights of protein
markers in kDa. (B) Western blot analysis confirms the IPTG-induced ~42 kDa protein is dNSurR9-C84A. The insoluble and soluble fractions in (A)
were Western blotted with a rabbit anti-survivin antibody, and immunoreactivity was detected with a peroxidase-conjugated goat anti-rabbit
antibody. Lane MW, molecular weights of protein markers in kDa. (C) Purification of GST-tagged dNSurR9-C84A by affinity chromatography on
glutathione agarose. The soluble fraction of lysates of IPTG-treated bacteria was chromatographed on glutathione agarose, and the glutathione
eluted material subjected to SDS-PAGE and stained with Coomassie blue. (D) Formation of 3D cellular spheres of DU145 and HeLa cancer cells.
Phase-contrast light microscopy of cellular spheres formed in semi-solid medium. (E) dNSurR9-C84A is able to penetrate into 3D-cultured DU145
and HeLa cells. Cells were incubated with dNSurR9-C84A for 1 to 5 h and cytoplasmic fractions Western blotted with an anti-GST antibody to
detect GST-tagged dNSurR9-C84A. Blots were probed with an anti-actin antibody as a control.
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endothelial cells (HUVEC) (Additional file 2) [28].
DU145 and HeLa cells grown in 3D cultures were incu-
bated for 36 h with 16, 48, 80 and 112 μg/mL (ie 1, 3, 5,
and 7 μM, respectively) of dNSurR9-C84A or with a
recombinant R9-tagged GST protein (7 μM) which
served as a negative control. dNSurR9-C84A at 7 μM
significantly (p < 0.01) reduced the cell viability of
DU145 and HeLa cancer cells by 60% and 70%, respec-
tively (Figure 2B). In contrast, R9-GST at 7 μM had no
affect on cell viability (Figure 2B). Thus, dNSurR9-C84A
is active in inducing the death of survivin-dependent
cancer cells grown in 3D culture.
dNSurR9-C84A increases the activity of caspases-3 and 9
in a time-dependent fashion
Targeting of survivin expression has previously been
shown to induce cancer cell death through activation of
intrinsic apoptosis mediated by caspases-3 and 9
[10,29,30]. In order to determine whether dNSurR9-
C84A decreases cell viability via activation of caspases,
Figure 2 dNSurR9-C84A induces cancer cell death. (A) Total lysates of 3D-cultured DU145 and HeLa cells were Western blotted with an anti-
survivin antibody which indicated endogenous expression of survivin. Blots were probed with an anti-actin antibody as a control. (B) dNSurR9-
C84A induces cancer cell death in a concentration-dependent manner. 3D cultures of DU145 and HeLa cells were treated with dNSurR9-C84A
for 36 h and cell viability measured by MTT assay. A statistically significant difference in the viability of cells treated with dNSurR9-C84A versus
R9-GST is denoted by “*”. *p < 0.05.
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the activities of caspase-3 and 9 were measured in
DU145 and HeLa cancer cells treated with 5 μM of
dNSurR9-C84A. dNSurR9-C84A increased the activity
of caspases-3 and 9 by 100 to 150% (p < 0.05) in both
cancer cell lines, compared to control treated cells
(Figure 3A, B). The activity of caspase-9 was induced as
early as 6 h post-treatment in DU145 and HeLa cells,
and returned to background levels at 18 h post-treat-
ment (Figure 3A). The induction of caspase-3 activity
was delayed compared to that of caspase-9. Increased
caspase-3 activity was seen in HeLa cells at 6 h post-
treatment, but not until 12 h post-treatment in the case
of DU145 cells (Figure 3B). Further, the activity of cas-
pase-3 steadily increased with time in both cell lines
reaching a peak at 18 h post-treatment. In contrast,
treatment of the cells with R9-GST did not lead to an
increase in the activity of the caspases compared to the
PBS control.
Figure 3 dNSurR9-C84A upregulates the activity of caspase-9 and caspase-3 in cancer cells. (A, B) 3D cultures of DU145 and HeLa cells
were treated with dNSurR9-C84A, R9-GST and PBS, and the activities of caspase-9 (A) and caspase-3 (B) were measured 6, 12 and 18 h post-
treatment. A statistically significant difference in caspase activity between cells treated with dNSurR9-C84A and R9-GST is denoted as “*”. *p <
0.05.
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dNSurR9-C84A restores cell sensitivity to TNF-a via
activation of caspase-8
Here we investigated the possibility that dNSurR9-C84A
might activate the caspase-8-mediated pathway of
extrinsic apoptosis, and thereby augment the efficacy of
TNF-a treatment of cancer. DU145 is an androgen-
independent prostate cancer cell line that displays resis-
tance to TNF-a treatment [31]. As would be expected,
combinational treatment of DU145 cells with R9-GST
and TNF-a (10 to 110 ng/mL) for 36 h had no affect on
cell viability (Figure 4A). In contrast, treatment with the
combination of 3 μM dNSurR9-C84A and TNF-a (50 to
110 ng/ml) caused a marked reduction in cell viability
(Figure 4A). The reduction in cell viability was asso-
ciated with significant 130, 90 and 140% increases in
caspase-3 activity, compared to treatment with R9-GST
(p < 0.05), dNSurR9-C84A (p < 0.05), and R9-GST in
combination with TNF-a (p < 0.05), respectively (Figure
4B). These results demonstrate that antagonism of survi-
vin renders DU145 prostate cancer cells sensitive to the
proapoptotic effects of TNF-a.
TNF-a induces cell apoptosis through the activation
of caspase-8 which leads to the subsequent activation of
caspase-3 [32]. Down-regulation of survivin by siRNA
does not induce the activation of caspase-8 in cancer
cells [33]. Here we asked whether the combinational
treatment of 3D-cultured DU145 cells with dNSurR9-
C84A and TNF-a leads to activation of caspase-8. As
expected, treatment of DU145 cells with 3 μM
dNSurR9-C84A did not increase the activity of caspase-
8, compared to cells treated with R9-GST or PBS
(Figure 5A). In contrast, treatment of cells with the
combination of 50 ng/mL of TNF-a and 3 μM
dNSurR9-C84A significantly increased caspase-8 activity
at 6 h post-treatment by 125 (p < 0.01), 75 (p < 0.05),
and 124 (p < 0.05)%, compared to treatment with PBS,
TNF-a, and dNSurR9-C84A, respectively (Figure 5B).
The increased caspase-8 activity returned to background
levels by 12 h post-treatment. Inclusion of 5 μM of the
caspase-8 inhibitor Z-IETD-FMK significantly (p < 0.05)
inhibited the decrease in cell viability of DU145 cells
caused by treatment with the combination of TNF-a
and dNSurR9-C84A (Figure 5C).
Discussion
The protein expression profiles of 2D and 3D-cultured
cancer cells are different [34]. In comparison to 2D-cul-
tured cells, the behavior of cells cultured under 3D condi-
tions is more reminiscent of that of cells growing in situ
[34]. Hence 3D cell cultures represent an improved in
vitro system to model the behavior of potential therapeutic
drugs. Here we used a 3D cell culture system to test the
ability of the survivin antagonist dNSurR9-C84A to kill
prostate and cervical cancer cells. This is the first report of
the production and characterization of a “cell-permeable”
recombinant form of survivin in which cysteine at position
84 in the zinc-coordination site in the BIR domain has
been substituted with alanine. The architecture of the BIR
domain is disturbed by mutation of the C84 residue to ala-
nine, and the ability of survivin to dimerize and interfere
with caspases is inhibited [21-23]. Herein, we revealed that
dNSurR9-C84A was able to kill 3D-cultured prostate and
cervical cancer cells, where killing was associated with
increased levels of caspase-3, and with DNA fragmentation
in the case of DU145 cells. Further, dNSurR9-C84A ren-
dered prostate cancer cells sensitive to the proapoptotic
effects of TNF-a by potentiating the upregulation of cas-
pase-8 activity, suggesting that survivin inhibits the extrin-
sic pathway of apoptosis. In accord, melatonin has been
shown to reduce both survivin and Bcl-2 protein levels
and subsequently increase the sensitivity of human PC3
prostate cancer cells to TNF-a [35]. Further, adhesion of
the aggressive prostate cancer cell line PC3 to fibronectin
results in upregulation of survivin and protects the cells
from apoptosis induced by TNF-a [36]. Adenoviral
expression of dominant negative T34A survivin counter-
acted the ability of fibronectin to protect the cells from
undergoing apoptosis, whereas wild-type survivin pro-
tected non-adherent cells from TNF-a-induced apoptosis.
It remains to be determined whether survivin inhibits
TNF-a signaling through direct interaction with caspase-
8 or via an indirect interaction, but at least one study
indicates a direct interaction is unlikely [10]. Survivin is
believed to be primarily involved in the intrinsic apopto-
sis pathway. Biochemical and structural analysis revealed
that survivin physically binds to caspase-3 and caspase-7
and inhibits their activities [8,10]. Therefore, it is possible
that survivin interferes with the TNF-a simulated apop-
tosis through both indirect regulation of the caspase-8
activity and direct regulation of caspase-3 activity.
Our laboratory has previously shown that intratumoral
delivery of a plasmid expressing dNSur-C84A causes
tumour apoptosis in an animal model of lymphoma
[22]. However, gene therapy clinical trials are hindered
by immune responses that can lead to overwhelming
inflammation and the death of patients [37]. It is perti-
nent to devise other treatment forms where gene ther-
apy proves to be problematic. Macromolecular protein
approaches targeting tumour survival factors, as exem-
plified here with dNSurR9-C84A may hold promise for
therapy.
Conclusions
In conclusion, a cell-permeable form of the dominant-
negative (C84A) survivin protein has been successfully
produced, and demonstrated to exert biological activity
in being able to kill prostate and cervical cancer cells.
Importantly, it was discovered that dNSurR9-C84A
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antagonizes survivin’s ability to suppress TNF-a signal-
ing, rendering prostate cancer cells susceptible to the
proapoptotic effects of TNF-a. dNSurR9-C84A is a both
a novel tool for probing the function of survivin, and a
potential therapeutic agent for augmenting cancer
therapy.
Materials and methods
Cell Lines, antibodies and reagents
The cell lines DU145 (human prostate carcinoma), and
HeLa (cervical epithelial carcinoma) were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA). DU145 cells were cultured in a mixture
Figure 4 dNSurR9-C84A renders DU145 cancer cells susceptible to the proapoptotic effects of TNF-a. (A) 3D cultures of DU145 cells
were treated with either R9-GST or dNSurR9-C84A in combination with increasing concentrations of TNF-a for 36 h, and cell viability measured
by the MTT assay. (B) 3D cultures of DU145 cells were treated with either R9-GST or dNSurR9-C84A alone or in combination with TNF-a for 18 h
and the activity of caspase-3 was measured. A statistically significant difference versus R9-GST is denoted as “*”. *p < 0.05.
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Figure 5 dNSurR9-C84A in combination with TNF-a upregulates the expression of caspase-8 activity. (A) dNSurR9-C84A does not induce
caspase-8 activity in 3D cultured DU145 cells. Cells were treated with PBS, R9-GST and dNSurR9-C84A for 6 to 12 h and the activity of caspase-8
measured. (B) dNSurR9-C84A potentiates the upregulation of caspase-8 in response to TNF-a. 3D-cultures of cells were treated with PBS, TNF-a,
dNSurR9-C84A and the combination of dNSurR9-C84A and TNF-a for 6 and 12 h. The activity of caspase-8 was measured. A statistically
significant difference in the caspase-8 activity of cells treated with the combination of dNSurR9-C84A and TNF-a versus TNF-a alone is denoted
as “*”. *p < 0.05. (C) 3D-cultures of DU145 cells were treated with PBS, TNF-a, dNSurR9-C84A, and the combination of dNSurR9-C84A and TNF-a
in the presence or absence of the caspase-8 specific inhibitor Z-IETD-FMK for 36 h. Cell viability was assessed by the MTT assay. A statistically
significant difference in the caspase-8 activity of cells treated with the combination of dNSurR9-C84A, TNF-a, and Z-IETD-FMK versus the
combination of dNSurR9-C84A and TNF-a is denoted as “*”.*p < 0.05.
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of Matrigel™(BD Biosciences, San Jose, CA) and RPMI-
1640 (Gibco, Grand Island, NY) in a 1:1 ratio. HeLa
cells were cultured in a mixture of Matrigel and Dulbec-
co’s modified Eagle medium (DMEM) (Gibco, Grand
Island, NY) in a 1:1 ratio. Both the latter media were
supplemented with 10% foetal bovine serum, penicillin
(100 U/mL), streptomycin (100 μg/mL) and L-glutamine
(0.29 mg/mL). Cells were cultured in the semi-solid
medium for five days to allow the formation of three
dimensional cellular spheres. Antibodies used in this
study included a goat anti-GST antibody (Amersham
Biosciences, Freiburg, Germany) and a rabbit anti-
human/mouse survivin antibody (Alpha Diagnostic, San
Antonio, TX).
Construction of a dominant-negative survivin expression
vector
A dominant-negative cell-permeable form of survivin
(dNSurR9-C84A) comprising 9 N-terminal arginine resi-
dues (R9, cell-permeable peptide carrier) fused to the
C84A dominant-negative survivin mutant was constructed
for the study. Briefly, the cDNA of a pcDNA3 expression
plasmid encoding dominant-negative survivin which con-
tains the entire coding region of mouse survivin (nucleo-
tides 75-583; GenBank accession No. NM_009689) and a
T-to-G substitution at nucleotide 354 that changes the
cysteine residue at amino acid 84 in the extreme C-term-
inal region of the BIR domain to an alanine was amplified
using the sense primer 5’- GGGGATCCATGCGACGAC-
GACGACGACGACGACGACGAGGAGCTCCGGCG
CTGCCCCAG-3’ (encodes R9) and the antisense primer
5’-GGGATCCTTAGGCAGCCAGC-3’[22]. The resulting
PCR product was subcloned into pGEM-T (Promega
Corp., Madison, WI), excised by digestion with BamHI,
and cloned into the expression vector pGEX-2T (Pharma-
cia Biotech, Piscataway, NJ) to give the vector pGEX-2T/
dNSurR9-C84A. The integrity of the pGEX-2T/dNSurR9-
C84A vector was confirmed by DNA sequence analysis.
Production of a recombinant dominant-negative survivin
protein dNSurR9-C84A
The dNSurR9-C84A expression vector was transformed
into DH5a bacteria, and the transformants were cultured
at 37°C in LB medium containing 100 mg/L of ampicillin.
When the OD600 nm reached 0.7, protein expression was
induced with IPTG (0.7 mM) (Invitrogen, Carlsbad, CA)
at 30°C for 3 h. The bacteria were pelleted and lysed in
STE buffer containing 0.1 mg/ml of lysozyme, 10 mM
dithiothreitol and 0.7% sarkosyl, and sonicated for 30 sec.
The GST-tagged recombinant dNSurR9-C84A protein
was purified by glutathione-Sepharose chromatography,
and dialyzed twice against PBS.
SDS-PAGE and Western blotting
Cells were lysed with lysis buffer (10 mM Tris, 1 mM
EDTA, 1 mM DTT, 60 mM KCl, 0.5% NP-40 and
Complete Protease Inhibitor Cocktail Tablet from
Roche, Germany, containing a mixture of protease
inhibitors), and proteins were resolved on 12% polya-
crylamide SDS gels under reducing conditions. The
gels were either stained with Coomassie blue or pro-
teins electrophoretically transferred to Hybond C Extra
nitrocellulose membranes (Amersham Life Science,
Amersham, UK). The membranes were blocked over-
night at 4°C with 5% non-fat milk powder, incubated
with primary antibodies for 90 min at RT, and then
with a horseradish peroxidase-conjugated secondary
antibody (Sigma Chemical Co., St Louis, MD). Immu-
noreactivity was detected by Enhanced Chemilumines-
cence (ECL) (Amersham International, Buckingham,
UK) and autoradiography.
Cell viability assays
Cells (4 × 103) were cultured in a semi-solid culture
medium comprised of Matrigel™and RPMI for five days
to allow the formation of three dimensional cellular
spheres. The cellular spheres were treated with test
reagents for 36 h. Dispase (BD Biosciences, San Jose,
CA), a bacillus-derived neutral metalloprotease, was
used to recover cells cultured in the Matrigel™. Live
cells were resuspended in PBS and cell viability was ana-
lyzed with the CellTiter96 MTS cell proliferation assay
kit (Promega Corp., Madison, WI) with measurements
being made on a 96-well plate reader (Bio-Tek Instru-
ments Inc.).
Measurement of caspase activity
The activity of caspase-3 in cell lysates was determined
with the Apo-ONE® Homogeneous Caspase-3/-7 apopto-
sis detection kit (Promega Crop., Madison, WI). Cas-
pase-8 activity was determined with the Caspase-8
Fluorometric Protease Assay Kit (Biovision, Mountain
View, CA). Caspase-9 activity was determined with the
Caspase-9 Fluorometric Protease Assay Kit (Biovision,
Mountain View, CA).
Measurement of DNA fragmentation
Cells were stained with the TUNEL reagent (In-Situ
Apoptosis Detection kit, Roche Diagnostic, Mannheim,
Germany) to detect DNA fragmentation, counter-stained
Cheung et al. Cancer Cell International 2010, 10:36
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with propidium iodide (PI), and examined by fluores-
cence microscopy.
Statistical analysis
The Student’s t-test was used with p < 0.05 indicating a
statistically significant difference.
Additional material
Additional file 1: dNSurR9-C84A is rapidly taken up by DU145 cells.
DU145 cells were incubated with either PBS (control) or dNSurR9-C84A
protein for 30 min. Cells were stained with an anti-GST antibody and
counter-stained with DAPI. Cells were examined by standard
immunofluorescence microscopy (top 2 rows) or by confocal microscopy
(bottom row). Green fluorescence indicates the presence of GST-tagged
dNSurR9-C84A in the cytoplasm. The cells were photographed, and the
images merged (right-hand panels).
Additional file 2: dNSurR9-C84A inhibits the viability of DU145 and
HeLa cells. (A) Cells were incubated with either PBS (control) or
increasing concentrations of dNSurR9-C84A for 12 h, and cell viability
was assessed. A statistically significant difference in the viability between
cells treated with dNSurR9-C84A and PBS is denoted as “*”. *p < 0.05. (B)
dNSurR9-C84A induces caspase-3/-7 activities in DU145 cells in a dose-
dependent fashion. DU145 cells were incubated with increasing
concentrations of dNSurR9-C84A for 90 min. The cells were lysed and
caspase-3/-7 activity in the cell lysate measured. A statistically significant
difference in the caspase activity between cells treated with dNSurR9-
C84A and PBS was denoted as “*”. *p < 0.05. (C) dNSurR9-C84A induces
DNA fragmentation in DU145 cells. Cells were incubated with PBS or
dNSurR9-C84A for 3 h, and stained (green) with the TUNEL agent. The
permeabilized cells were counter-stained (red) with propidium iodide.
Abbreviations
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